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There is substantial variation in the relapse frequency of Plasmodium vivax
malaria, with fast-relapsing strains in tropical areas, and slow-relapsing strains
in temperate areas with seasonal transmission. We hypothesize that much
of the phenotypic diversity in P. vivax relapses arises from selection of relapse
frequency to optimize transmission potential in a given environment, in a pro-
cess similar to the virulence trade-off hypothesis. We develop mathematical
models of P. vivax transmission and calculate the basic reproduction number
R0 to investigate how transmission potential varies with relapse frequency
and seasonality. In tropical zones with year-round transmission, transmission
potential is optimized at intermediate relapse frequencies of two to three
months: slower-relapsing strains increase the opportunity for onward trans-
mission to mosquitoes, but also increase the risk of being outcompeted by
faster-relapsing strains. Seasonality is an important driver of relapse frequency
for temperate strains, with the time to first relapse predicted to be six to
nine months, coinciding with the duration between seasonal transmission
peaks. We predict that there is a threshold degree of seasonality, below
which fast-relapsing tropical strains are selected for, and above which slow-
relapsing temperate strains dominate, providing an explanation for the
observed global distribution of relapse phenotypes.1. Introduction
Plasmodium vivax malaria is endemically transmitted or has been historically
endemic across the globe in regions with extremely diverse climates [1,2], from
temperate locations such as Finland [3] to Papua New Guinea in the tropics [4].
A notable exception is in large parts of sub-Saharan Africa where high prevalence
of theDuffy-negative phenotype renders populations relatively resistant toP. vivax
infection [5], even though the more virulent Plasmodium falciparum malaria is
highly prevalent. A fundamental difference between these species of malaria
is the ability ofP. vivax parasites to remain latent in the liver following an infectious
mosquito bite, activatingweeks tomonths later to cause relapses [6]. Relapses play
an important role in the transmission of P. vivax and account for its potential for
sustained transmission in such a diverse range of environmental niches.
Plasmodium vivax is conventionally classified according to whether relapses
follow a tropical or temperate phenotype [6–8]. In tropical regions with year-
round mosquito-borne transmission, relapses occur rapidly at a frequency of three
to six weeks. In temperate regions where mosquito-borne transmission is possible
only in the summer months [1], the time to first relapse is typically 6–12 months
[7]. Notably, after the first relapse of a temperate phenotype, multiple subsequent
relapses are often observed to occur rapidly [6,9]. In some regions such as India
andCentralAmerica [10], intermediatephenotypes, orbothphenotypes, arepresent.
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zoites are inoculated into the human skin and travel to the liver
where they invade hepatocytes. A proportion of these sporo-
zoites will immediately undergo hepatic development giving
rise to primary blood-stage infection 9–10 days later [11].
Some sporozoites will transform into hypnozoites, remaining
silent and undetectable in the liver for weeks to months until
they resume development to cause relapses [7]. The mechan-
isms regulating hypnozoite activation remain unknown [12],
although it has been proposed that relapses may be triggered
by fevers from other infections [6,13] or exposure to mosquito
bites [14]. Many of the patterns of observed relapse timings
are consistent with hypnozoites activating at a constant rate,
without the need for external triggers [15].
The hypnozoite activation rate and resulting relapse fre-
quency will influence the transmission potential of P. vivax.
For tropical strains of P. vivax, slow-relapsing strains may be
outcompeted by faster-relapsing strains. However, if hypno-
zoites activate very quickly, then the resulting blood-stage
infectionmay coincidewith blood-stage parasites from the pri-
mary infection. Assuming human-to-mosquito transmission
probability remains constant and independent of blood-stage
density [16], the potential for transmission to mosquitoes will
be optimized by maximizing the expected duration of blood-
stage infection, whether from primary infection or relapses.
For temperate strains of P. vivax, the optimal time to relapse
will additionally be affected by the seasonality of mosquito-
borne transmission. In such settings, transmission potential is
likely to be optimized by strains that remain dormant over
thewintermonths when the potential for blood-stage parasites
to be transmitted to mosquitoes is low.
The virulence trade-off hypothesis asserts that pathogens are
under selective pressure to optimize transmission potential [17].
For example, it has been argued that the average density
of blood-stage malaria infections has evolved to maximize
onwards transmission to mosquitoes, but only to the point
where the benefit to transmission is not outweighedby increased
host mortality [18]. Similarly, the set-point viral load of HIV is
under selective pressure to optimize the number of transmission
events [19]. Too high a viral load, and infected individuals are
likely to die before they can transmit. Too low a viral load, and
the probability of transmission per infectious contact is reduced.
We propose that for P. vivax, the hypnozoite activation rate
and the duration of dormancy (for temperate strains) are under
selective pressure to optimize transmission potential in a given
environmental niche. We develop mathematical models of
malaria transmission accounting for the patterns of relapses
arising from hypnozoites, butwith the simplifying assumption
that variations in blood-stage density are ignored, and test the
hypothesis that optimal relapse frequencies depend on the dur-
ation of P. vivax blood-stage infection and the seasonality and
intensity of transmission.2. Material and methods
(a) Within-host model of Plasmodium vivax relapses
Following primary infection with a tropical strain of P. vivax, hyp-
nozoites enter a latent stage in the liver where they either activate
to cause relapses, or die within liver hepatocytes. An existing
within-host model [15] is used to describe the progress of liver-
stage infection and the resulting relapse patterns. The model is
determined by the following biological parameters:— N: expected number of hypnozoites per infectious mosquito
bite,
— a: hypnozoite activation rate,
— m: hypnozoite death rate.
Hypnozoite activation in the absence of blood-stage infection
leads to the occurrence of a relapse. When hypnozoites activate in
the presence of blood-stage infection, a relapse also occurs but it
may or may not be detected owing to the existing blood-stage para-
sites. Notably, hypnozoites are assumed to act independently of one
another, and the potential role of external relapse triggers is ignored.
Following primary infection with a temperate strain, hypno-
zoites enter a long-latent stage where activation to cause relapses
does not immediately occur [7]. We refer to this period of
long-latency as the dormant stage. After dormancy, we assume
that hypnozoitesprogress to the latent stagewhere activation is poss-
ible. There is much uncertainty related to the biology of temperate
strains of P. vivax relapses. Most notably, the biologicalmechanisms
responsible for the period of dormancy before the first relapse are
poorly understood [12]. Two hypotheses that have been proposed
are that hypnozoites spend predetermined intervals in the dor-
mancy stage before relapses can occur (e.g. an epigenetic clock)
[20,21], or that hypnozoites are activated by some external trigger
[6,13]. Here we develop the mathematical details of the epigenetic
clockmodel where hypnozoites must initially undergo a dormancy
stage before switching to a latency stage where they can relapse.
Characterizing the extended period of time before first
relapse of temperate strains of P. vivax relapses requires an
additional parameter:
— d: duration of dormancy.
During dormancy, it is assumed that hypnozoites cannot
activate to cause relapses. However, we assume that hypnozoites
may still die owing to hepatocyte death [22]. The duration of dor-
mancy of temperate strains can be described by a number of
distributions [8,23]. Here we test cases where it follows an expo-
nential distribution with rate parameter d ¼ 1/d, or a gamma
distribution with mean d and standard deviation sd (see the
electronic supplementary material for details).
(b) Binary model of Plasmodium vivax relapses
Awithin-host model can track hypnozoites in the liver, accounting
forhowrelapsepatternsdependonhypnozoitenumbers.However,
tracking hypnozoite numbers as opposed to binary infection status
substantially increases analytic complexity.We can formulate a sim-
pler relapsemodelwithhypnozoite infectionof the liver viewedasa
binary process. The epidemiology of tropical strains of P. vivax can
then be described by three key parameters:
— f : relapse frequency (, 1/time to next relapse),
— h: number of relapses per primary infection, and
— gL: rate of clearance of liver-stage infection.
Using relationships derived byWhite et al. [15], the parameters
describing hypnozoite infection as a binary state can be expressed
in terms of the within-host parameters of hypnozoite biology.
h ¼ N a
mþ a , ð2:1Þ
1
gL
¼ log(N þ 1Þ
mþ a ð2:2Þ
and f ¼ hgL ¼ a
N
log(N þ 1Þ : ð2:3Þ
The above equations capture the trade-offs between the par-
ameters for the epidemiology of P. vivax relapses. In particular,
equation (2.3) assumes a constant relapse rate, e.g. the expected
time to first relapse [7] is the same as the expected time between
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Figure 1. Schematic diagrams of malaria transmission models. The force of
infection owing to new mosquito bites is l ¼ mabIM. Parameter definitions
and values are provided in table 1. Model 1: non-relapsing P. falciparum
malaria. Model 2: relapsing P. vivax malaria of a tropical phenotype.
Model 3: relapsing P. vivax malaria of a temperate phenotype. Dashed
boxes denote states where an individual is harbouring dormant hypnozoites.
The models are built up by sequentially adding compartments for latent hyp-
nozoite stages, and compartments for dormant hypnozoite stages. Mosquito
compartments are not shown.
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model [15], which accounts for the increasing time between
subsequent relapses owing to the depletion of hypnozoites in
the liver [6,24].
Similar to the within-host model, the duration of dormancy
of temperate strains is described by the parameter d. Relapses
are not allowed to occur during the period of dormancy, how-
ever liver-stage infection can be cleared as hypnozoites may
still die owing to hepatocyte death [22]. This results in a slower
rate of clearance of infection during dormancy. Similar to the
expression for gL in equation (2.2), the rate of clearance of
liver-stage infection during dormancy is
1
gD
¼ log(N þ 1Þ
m
: ð2:4Þ
(c) Mathematical models of malaria transmission
Analysis of the transmission dynamics of non-relapsing
P. falciparummalaria is grounded in the theory of Ross-MacDonald
models [25,26]. Here, we describe how Ross-MacDonald models
can be expanded to account for relapses characteristic of tropical
and temperate strains of P. vivax. The compartmental model for
P. falciparum transmission can be extended to incorporate the
latent stages for relapses of tropical strains of P. vivax (figure 1).
This model can be further extended to incorporate the dormant
stages characteristic of temperate strains of P. vivax.
(i) Model 1: Plasmodium falciparum
Humans are assumed to be in one of two states: susceptible (S0)
or infected (I0). Mosquitoes are assumed to be in one of two
states: susceptible (SM) or infectious (IM). Mosquitoes that are
infected but not yet sporozoite positive are considered suscep-
tible. The force of infection on humans is given by l ¼ mabIM.
A schematic diagram of the model is presented in figure 1 and
equations are presented in the electronic supplementary material.
The basic reproduction number for P. falciparum malaria [32] as
described by this model is
RPf0 ¼
ma2bcegn
gr
: ð2:5Þ
(ii) Model 2: Plasmodium vivax (tropical)
The mathematical model for P. falciparum transmission outlined
in figure 1 can be extended to incorporate relapses of tropical
strains of P. vivax through the addition of states for latent hypno-
zoites. These states are denoted through sub-script L. Following
an infectious bite, an individual will develop blood-stage infec-
tion (from sporozoites that develop immediately) and latent
liver-stage infection (from sporozoites that transform into hypno-
zoites). Blood-stage infections clear at rate r. Liver-stage
infections clear at rate gL. Liver-stage infection is assumed to
cause new blood-stage infections through relapses at rate f. It is
assumed that relapses do not extend the duration of existing
blood-stage infections. The model is described by the following
system of differential equations:
dS0
dt
¼ lS0 þ rI0 þ gLSL,
dI0
dt
¼ lI0  rI0 þ gLIL,
dSL
dt
¼ lSL þ rIL  fSL  gLSL,
dIL
dt
¼ lðS0 þ I0 þ SLÞ  rIL þ fSL  gLIL,
dSM
dt
¼ g acðI0 þ ILÞðegn  IMÞ  gSM
and
dIM
dt
¼ acðI0 þ ILÞðegn  IMÞ  gIM:
9>>>>>>>>>>>=
>>>>>>>>>>>;
ð2:6ÞThe basic reproduction number will be proportional to the
expected time with blood-stage parasites owing to both primary
and relapse infections, and is given by
RPv0,L ¼
ma2bcegn
gr
1þ fr
gLð f þ rþ gLÞ
 
: ð2:7Þ
See the electronic supplementary material for details of the
derivation. If there are no relapses (i.e. f ¼ 0) then equation
(2.7) reduces to equation (2.5).(iii) Model 3: Plasmodium vivax (temperate)
The equations describing tropical strains of P. vivax can be
extended to incorporate the dormancy stage characteristic of
Table 1. Description of model parameters. Parameters are based on estimates from data on temperate strains from Central America [27]. The parameters for
the epidemiology of relapses describe the outcome following a single infectious bite.
parameter description value reference
humans
b transmission probability: mosquito to human 0.5 [28]
r rate of clearance of blood-stage infections 1/60 day21 [29]
N number of hypnozoites per infection 6.4
a rate of hypnozoite activation 1/230 day21
m rate of hypnozoite death 1/217 day21
d duration of temperate dormancy (d ¼ 1/d ) 162 days
sd standard deviation of temperate dormancy 49 days
K compartments for Gamma distribution ðK ¼ d2=s 2d Þ 11
h expected number of relapses 2.1
gL rate of hypnozoite clearance (latent stage) 1/223 day
21
f relapse frequency (1/time to next relapse) 1/72 day21
gD rate of hypnozoite clearance (dormant stage) 1/434 day
21
mosquitoes
a mosquito biting frequency 0.21 day21 [30]
g mosquito death rate (1/mosquito life expectancy) 0.1 day21 [1]
m number of mosquitoes per human varied
n duration of sporogony in mosquito 12 days [1]
c transmission probability: human to mosquito 0.23 [31]
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individual will develop blood-stage infection and dormant
liver-stage infection (from sporozoites that transform into hypno-
zoites). These hypnozoites will remain in the dormant stage for
an expected duration of d days, during which time relapse is
not possible. During dormancy, liver-stage infections may be
cleared by natural hepatocyte death at rate gD. After dormancy,
liver-stage infection progresses to the latent stage where hypno-
zoites can activate to cause relapses at rate f. Latent liver-stage
infections are assumed to clear at rate gL.
If we assume the duration of dormancy is exponentially
distributed, then the basic reproduction number is
RPv0,D ¼
ma2bcegn
gr
1þ dfrðdþ rþ lL þ gDÞ
gLð f þ rþ gLÞðdþ gDÞðdþ rþ gDÞ
 
:
ð2:8Þ
As the duration of dormancy approaches zero, equation (2.8)
simplifies to equation (2.7), i.e. as d! 1, RPv0;D ! RPv0;L. Similar
expressions can be derived when the duration of dormancy
follows a Gamma distribution [33].
(d) Seasonality in transmission
Seasonality in exposure to mosquitoes is accounted for using a
previously described periodic functional form [34]. The degree
of seasonality is measured as the proportion of exposure to mos-
quitoes occurring in the peak three months. The expressions for
R0 in equations [2.5,2.7,2.8] do not apply in seasonal settings, but
can be calculated numerically using Floquet theory [35]—see the
electronic supplementary material.
(e) Strain competition model
A method for modelling competition between many-strain
pathogens [36] was adapted for the malaria transmission
models in figure 1. The dynamics of co-circulating strains ofP. vivax with varying time to first relapse were simulated. Com-
petition between strains was mediated via cross-strain immunity
whereby the probability of infection with new strains reduces
with the multiplicity of infection [37].
( f ) Model parametrization
The within-host model was fitted to data from six cohorts where
participants were followed longitudinally for the detection of
relapses following primary P. vivax infection from either artificial
challenge or natural exposure [24,27,38–41]. Up to five relapses
were observed per individual, with treatment administered follow-
ing each infection. We assume that new blood-stage infections are
not possible for 14 days after each new relapse, based on the
duration of prophylactic protection of the administered treatment.
The models were fitted to the data using Approximate Baye-
sian Computation (ABC). This method was preferred over
likelihood-based methods owing to the difficulty in constructing
likelihoods that account for unobserved events during the obser-
vation period. The acceptance criteria for the ABC algorithm was
based on agreement between model predictions and 95% CIs
from survival analysis of the data. Further details are in the
electronic supplementary material.3. Results
(a) Epidemiological parameters of Plasmodium vivax
relapses
Figure 2 shows examples of model fits to datasets from tropical
relapse phenotypes (Model 2, figure 2a) and temperate relapse
phenotypes (Model 3, figure 2b). The best-fit parameters for the
within-host model are provided in the electronic supplementary
material. The estimated within-host parameters were used to
obtain estimates of the relapse parameters for the binary
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Figure 2. (a) Tropical and (b) temperate relapse phenotypes. Comparison between model predicted survival time until nth relapse and data from six cohorts. After
primary infection, participants in each cohort were followed longitudinally for the detection of relapses. Up to five relapses were detected per participant with
treatment administered following each detected relapse. Data are presented using survival analysis to show the proportion of individuals with at least n relapses
(circles) and 95% confidence intervals (vertical lines). The duration of dormancy for the temperate relapse phenotype is described by a gamma distribution. The solid
curves shows the best-fit prediction from the within-host model (number of hypnozoites accounted for) and the dashed curves denote the prediction from the binary
model (hypnozoite infection regarded as a binary state). The close agreement between the solid and dashed curves suggests that the within-host biology of hyp-
nozoites and subsequent relapses can be approximated by simpler binary models. All parameter values are provided in the electronic supplementary material.
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ings predicted by the binary model are also plotted in figure 2.
The close agreement between predicted relapse timings in
figure 2 demonstrates that the relapse patterns predicted by
detailed within-host models [15] can be approximated by the
simpler binary models from figure 1. Notably, the time to next
relapse is memoryless for the binary model and does not
depend on the number of previous relapses. However, for the
within-host model, the time to next relapse depends on the
number of hypnozoites in the liver and hence the number of
past relapses.
(b) Optimizing the transmission potential of
Plasmodium vivax in non-seasonal settings
Figure 3a shows how the expected number of relapsing
hypnozoites is predicted to decrease with slower hypnozoite
activation rates. Note that if several hypnozoites activate
within a short period of time (e.g. a fewdays) theymay be classi-
fied as a single relapse. Figure 3b showshow thedurationof time
spent in the liver increases for slowerhypnozoite activation rates.
Figure 3c shows howR0 is optimized at intermediate values ofa
(corresponding to intermediate relapse frequencies),where there
is a balance between hypnozoites waiting for the primary infec-
tion to clear before relapsing, but not waiting too long to risk
death in liver hepatocytes [22]. This maximizes the time that
transmissible parasites spend in the blood (arising from either
primary infection or relapses). For tropical strains, R0 is maxi-
mized when the hypnozoite activation rate a  1/206 days,
corresponding to a relapse frequency of f  1/64 days. A similar
pattern isobserved for temperate strains, although increasing the
duration of dormancy reduces the expected number of relapsing
hypnozoites, and increases the duration of liver-stage infection.(c) Variation of transmission potential of Plasmodium
vivax in seasonal settings
Increasing thedegreeof seasonalityofmalaria transmission ispre-
dicted to reduce R0 for non-relapsing P. falciparum (figure 4a).
Tropical strains of P. vivax are predicted to exhibit modest vari-
ation in transmission potential with variation in seasonality.
By contrast, the transmission potential of temperate strains of
P. vivax is predicted to increase in more seasonal settings.
Figure 4b shows how the transmission potential of temperate
strains of P. vivax depends on the duration of dormancy. In
more seasonal settings, R0 is maximized at longer durations of
dormancy, such that the time to first relapse coincides with the
period between transmission peaks. The model proposed here
canbeused topredict relapse frequencies foragivenseasonalpro-
file (figure 4c). For temperate strains of P. vivax the duration of
dormancy, and hence the time to first relapse, are predicted to
increase with seasonality. There is a notable switch in optimal
relapse times, from 3–4 months in low-seasonality settings
(characteristic of tropical zones), to 7–8 months in high-
seasonality settings (characteristic of temperate zones), in
agreement with epidemiological observations [7,8,27,40,41].
(d) Variation in relapse frequency with transmission
intensity
Optimizing R0 maximizes the number of secondary infections
arising from a single individual in an otherwise susceptible
population. However, this may be at the expense of longer
generation times (the expected time between primary infec-
tion in a human and primary infection in another human
after one generation of transmission). For tropical strains of
P. vivax, figure 5 shows how the predicted equilibrium
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across a range of transmission intensities. At very low trans-
mission intensity when most of the population is susceptible,
PvPR is optimized at the same relapse frequency that opti-
mizes R0. As transmission intensity increases, the time to
next relapse that maximizes PvPR decreases. The advantage
of waiting in the liver diminishes because a hypnozoite-
infected individual may receive another primary infection
from a mosquito before the hypnozoite has a chance to relapse.
In particular, as transmission intensity increases the time to
relapse that maximizes PvPR approaches zero. Conversely,
if P. vivax transmission is reduced through malaria control
interventions, slower-relapsing strains may be selected for.
(e) Competition between strains of varying relapse
frequency
The previous analyses investigated transmission potential in
terms of R0 (figures 3 and 4) or equilibrium parasite prevalence
(figure 5), but did not consider direct competition between
strains with different relapse frequencies. Figure 6 shows thesimulated dynamics of 200 strains of temperate P. vivax with
varying durations of dormancy d. The distribution of d in these
strains initially followed a zero-truncated normal distribution
with a mean of two months and standard deviation of three
months. In the low-seasonality setting, fast-relapsing strains are
selected, with time to first relapse approaching four months. In
the high-seasonality setting, slower-relapsing strains are selected
forwith the time to first relapse coincidingwith the timebetween
consecutive seasonal peaks at around eight months.4. Discussion
Relapses are a key driver of P. vivax transmission [15], with the
fitness of P. vivax strongly influenced by relapse frequency.
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primary infection to clear, another primary infection will occur. Slower relapses
are favoured at lower prevalence because hypnozoites can safely wait for the
primary infection to clear before relapsing. The vertical dashed line corresponds
to the time to first relapse ( f ¼ 66 days) that optimizes R0.
tim
e 
to
 fi
rs
t r
el
ap
se
 (m
on
ths
)
0
2
4
6
8
10
12
tim
e 
to
 fi
rs
t r
el
ap
se
 (m
on
ths
)
0
2
4
6
8
10
12
2
time (years)
time (years)
high-seasonality setting
low-seasonality setting
1084 6
0
0
2 1084 6
0 2
strain prevalence (%)
84 6
Figure 6. Competition between temperate strains of P. vivax with varying time
to first relapse. The time to first relapse was varied by changing the duration of
dormancy d while keeping the average time in the latent stage fixed (1/f ).
Simulations were initialized with the distribution of strain phenotype assumed
to follow a normal distribution. In a low seasonality setting, the mean time to
first relapse converges on approximately four months. In a high-seasonality
setting, the mean time to first relapse converges on six to nine months.
rspb.royalsocietypublishing.org
Proc.R.Soc.B
283:20160048
7
 on August 5, 2016http://rspb.royalsocietypublishing.org/Downloaded from Here we predict that transmission potential is optimized at
intermediate relapse frequencies that balance the benefits of
slow-relapsing strains (longer total duration of blood-stage
parasitemia) with the benefits of fast-relapsing strains
(increased probability that parasites are transmitted quickly
before hypnozoites die in liver hepatocytes). This trade-off
provides insight into the globally observed variation in
P. vivax relapse frequency, and the potential effects on relapse
frequency of reducing transmission through malaria control.
Seasonality has been recognized as an important driver of
the transmission potential of many pathogens [42,43]. Here,
we demonstrate how seasonality in exposure to mosquitoes,
driven by seasonal fluctuations in temperature and rainfall [1],
affects the transmission potential of P. vivax. Our analysis pre-
dicts that the time to first relapse increases with the degree of
seasonality of transmission. Notably, as seasonality increases,
there is a sharp switch from short duration of dormancy (tropi-
cal phenotype) to a long duration of dormancy (temperate
phenotype). This suggests that in areas where P. vivax is ende-
mic, circulating strains will be either tropical or temperate, but
not both.However, themodel did not consider the complex sea-
sonal patterns of transmission observed in places such as India
[44], where both phenotypes are present.
This analysis suggest that relapse frequencies depend on
the intensity and seasonality of malaria transmission in
the absence of relapse triggers such as fevers induced by co-
circulating pathogens such as P. falciparum [6]—an important
limitation. While triggers may add an additional layer of
complexity to relapse patterns, their role is unlikely to affect
the findings of this analysis. A further limitation relates to the
density of blood-stage infections [29]. Although relapses may
play a role in increasing blood-stage parasite densities, we
assume constant human-to-mosquito transmission probability
throughout blood-stage infection, despite evidence that
higher gametocyte densities are associated with increased
transmission probability [45]. This has implications for the
virulence trade-off hypothesis [17], which has beeninvestigated for malaria [18,46]: increasing parasite densities
lead to higher probability of transmission to mosquitoes, but
also increased hostmortality and shorter durations of infection.
The trade-off in relapse rates to optimize P. vivax transmission
potential can be considered a corollary of the virulence trade-
off hypothesis. Although not accounted for in the analytic
models presented here, the additional complexity arising
from within-host processes regulating blood-stage parasites
can be addressed using simulation models [16].
In the framework considered here, the transmission
potential of P. vivax is optimized by maximizing the time
that an infected individual spends with blood-stage parasites.
The early generation of P. vivax gametocytes ensures that
onward transmission to mosquitoes is likely throughout
blood-stage infection [45]. In an otherwise susceptible popu-
lation, the conditions for optimal transmission potential are
the same as the conditions for maximum R0. However, in set-
tings with high P. vivax prevalence, transmission potential
will be affected by primary infections from new mosquito
bites. For example, in a high transmission setting an individ-
ual infected with a slow-relapsing strain may receive a second
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 on August 5, 2016http://rspb.royalsocietypublishing.org/Downloaded from infection from a new mosquito bite before the relapse from
the primary infection occurs. This causes faster-relapsing
strains to be selected for in high transmission settings.
The relationship between time to relapse and seasonality
predicted here is in agreement with epidemiological data on
the geographical distribution of relapses [7,8]. Furthermore,
our model suggests that observed strains have close to optimal
fitness for their geographical location, including in regions such
as South America where P. vivax was reportedly introduced
approximately 500 years ago [47]. As transmission is reduced
globally through increasedmalaria control all strainswill be tar-
geted, but the timeline to effectiveness will be more rapid for
faster-relapsing strains. Indeed, as malaria transmission is pro-
gressively reduced, the proportion of slow-relapsing strains
may increase. This change may arise as a consequence of the
higher transmission potential of existing circulating strains
with slow relapse frequency, or from the importation of
strains from other regions. Although the de novo evolution of
strains with slower relapse frequency is possible, it is unlikely
to be significant over the epidemiological timescales of interest.
Rapid scale-up of malaria control interventions may target all
strains of P. vivax, reducing the opportunity for slow-relapsing
strains to become established.A comparable argument has been
made for the widespread deployment of anti-retroviral treat-
ment for HIV to rapidly reduce HIV transmission before the
transmission trade-off can plausibly select strains of increasedvirulence [19]. Similarly, a strategy of rapid scale-up of malaria
control interventions may reduce the risk of an increased
proportion of slow-relapsing strains of P. vivax. Although fast-
relapsing strains may cause greater morbidity in infected
individuals, slow-relapsing strains may increase the timeline
to malaria elimination in a population with low levels of
P. vivax transmission long after P. falciparum has been
sustainably eliminated [48].Data accessibility. Data on relapse timings: Dryad: http://dx.doi.org/10.
5061/dryad.mg73v.
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